ClinicalTrials.gg
TerminatedNCT01660243Updated Feb 9, 2022Results posted

Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis

A Phase 2 interventional study of Nalfurafine hydrochloride(MT-9938) 2.5μg and Nalfurafine hydrochloride(MT-9938) 5μg in Uremic Pruritus, sponsored by Toray Industries, Inc. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Toray Industries, Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
This study has been terminated because of insufficient patient recruitment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing TRK 820 in Pruritus — 3 open to participants now, 3 under way, none of them phase 3. TRK 820 · Pruritus.

Enrollment
8th of 10
45 · median 99
Started
2012
the only one that year
Phase 2
2 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
3 of 10
Toray Industries, Inc

Among the 10 studies testing TRK 820 in Pruritus, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 2 in phase 2, and was the 4th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

3 of the 10 studies testing TRK 820 in Pruritus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About TRK 820

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing TRK 820 in Pruritus, or all of them as a file.
02

Study summary

This study is being conducted to investigate the efficacy of MT-9938 compared with placebo after 2 weeks, to continue to evaluate efficacy for an additional 6 weeks, and to explore the effect of a reduction in itching intensity on health-related Quality of Life(QoL) domains, especially those which recent research suggests have a positive correlation with overall survival for this patient group. The study will consist of the following phases: Screening (1 to 2 weeks), Run in (1 week), double-blind Treatment (8 weeks), Washout (1 week) culminating in a Follow-up Visit (1 week after the last dose).

Read the detailed description

This study has been terminated because of insufficient patient recruitment. There were no safety concerns.

03

Conditions studied

  • Uremic Pruritus

Keywords

  • Pruritus
  • Renal dialysis
  • Receptors, Opioid, kappa
  • Sleep Disorders
  • Quality of Life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • On stable hemodialysis for at least 3 months
  • Has stable functioning arteriovenous fistula, graft or other venous access
  • Has continued (uncontrolled) uremic pruritus despite standard of care in the institution
  • Has severe pruritus, as determined by a qualifying score of ≥3 on the Itch Severity Score Scale (0 to 4) either day or night during the week prior to Screening Visit
  • Has no known drug addiction to any prescription, nonprescription, herbal or natural drugs, and successfully passes a drug screen test
  • Women and men whose partners are of agree to practice the medically acceptable methods of and agree to continue with the regimen throughout the duration of the study
  • Capable of understanding and responding to the subject questionnaires, understands the purpose and risks of the study, and has given written
  • Has rated his/her NRS score each day for at least 5 days out of the 7 days of the Run-in Phase
  • Has severe pruritus, as determined by qualifying mean worst NRS score in a day of ≥5 (on 11 point NRS) at the end of the 1-week Run-in Phase

Exclusion criteria

Exclusion Criteria:

  • Current, medical comorbidities
  • Abnormal liver dysfunction
  • Pruritus attributed mainly to any disease unrelated to kidney disease
  • Calcium x phosphorus product >80 mg2/dL2 or \<7 g/dL or parathyroid hormone levels >1000 pg/mL at Screening
  • Received ultraviolet B treatment within 30 days prior to Screening
  • Started or changed psychotropic medication within 14 days prior to Screening
  • Is receiving opioid antagonists or opioid agonists within 7 days prior to Screening and not willing to abstain from these medications during the study.
  • Started or changed medications, creams or emollients including over-the-counter oil bath treatment for relief of pruritus within 7 days prior to Screening
  • Has known to opioids or the study drug ingredients
  • Is currently participating in an drug or device clinical study or was participating in such a study within 30 days prior to the start of Screening
  • Female subject who is known to be pregnant or nursing
  • Is considered not suitable for inclusion in the study in the opinion of Investigator
  • Has current suicidal ideation with some intent to act or with specific plan and intent or had suicidal behavior at any time in subject's life
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (actual)

Study arms

  • Active comparator
    MT-9938 2.5μg

    Drug: Nalfurafine hydrochloride(MT-9938) 2.5μg

  • Active comparator
    MT-9938 5μg

    Drug: Nalfurafine hydrochloride(MT-9938) 5μg

  • Active comparator
    MT-9938 10μg

    Drug: Nalfurafine hydrochloride(MT-9938) 10μg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Worst-itching 11-point Numerical Rating Scale (NRS)

    The subject indicated the number on the line from left (0:no itching) to right (10:worst itch I have ever experienced). Assessments was made twice daily using an electronic Patient Reported Outcomes (ePRO) device from the Screening Visit to the Follow-up Visit (Week 9). The 2 daily assessments was separated by 12 h, at approximately 8 am and at approximately 8 pm. Subjects selected the number that best described the worst itch during the day (assessed at approximately 8 pm) or during the night (assessed at approximately 8 am). The day or night score, whichever was greater, was used to calculate the weekly average score and changes from baseline (average over the Run-in Phase \[Days -7 to -1\]) score in weekly average at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.

    Time frame: 2 weeks, 4 weeks and 8 week

  2. Change From Baseline in Worst-itching Visual Analog Scale (VAS)

    The subject placed a single vertical mark on the line of a VAS corresponding to degree of itching intensity from left (no itching) to right (worst itch I have ever experienced). The VAS represents a 100 mm line. It consists of 101 selectable regions and the subject's score on the VAS will correspond to the region (0 to 100) selected on the line. Assessments was made twice daily using an ePRO device from the Screening Visit to the Follow-up Visit (Week 9). The 2 daily assessments was separated by 12 h, in the morning at approximately 8 am and in the night at approximately 8 pm. Subjects put a single vertical mark on the line to show the intensity of your worst itching during the day or during the night. The day or night score, whichever was greater, was used to calculate the weekly average score and changes from baseline in weekly average at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.

    Time frame: 2 weeks, 4 weeks and 8 weeks

  3. Change From Baseline in Itch Severity Score

    The subject performed an assessment on day and nighttime symptoms of itch and effect of itch on sleep using a 5-point ordinal scale of itchiness (0 = none, 1 = mild, 2 = Moderate, 3=Severe, 4 = very severe). Assessments was made during each dialysis treatment (3x/week) and recorded on paper from the Screening Visit to the Follow-up Visit (Week 9). Change from Baseline (average over the Run-in Phase \[Days -7 to -1\]) in Weekly Averages of Itch Severity Score were assessed and score at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.

    Time frame: 2 weeks, 4 weeks and 8 weeks

  4. Change From Baseline in Sleep Quality Assessment

    The PSQI has a minimum possible score of 0 (better sleep quality) and a maximum possible score of 10 (worse sleep quality). Subjects was asked to rate their sleep experience during the previous week. Pittsburgh Sleep Quality Index (PSQI) modified assessment was made during the dialysis treatment 1x/week every week and recorded on paper from the Screening Visit to the Follow-up Visit (Week 9).Change from Baseline (the Run-in Phase \[Days -7 to -1\]) were assessed and score at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.

    Time frame: 2 weeks, 4 weeks and 8 weeks

  5. Change From Baseline in QoL Assessment (Skindex-10)

    The Skindex-10 has a minimum possible score of 0 (itching not bothersome) and a maximum possible score of 60 (itching very bothersome). The Skindex-10 is a self-administered questionnaire used to evaluate the health-related QoL in UP. It is comprised of 10 questions, adopted for pruritus from the Skindex-16, a widely used instrument for a variety of skin disease. Subjects was asked to identify on paper at Baseline and Weeks 2, 4, and 8 (EOT) what has bothered them most during the past week by marking along a scale 0 to 6 boxes from "never bothered" to "always bothered. Change from Baseline (the Run-in Phase \[Days -7 to -1\]) were assessed. Amount of change score of plus indicates worsening, and minus indicates improvement.

    Time frame: 2 weeks, 4 weeks and 8 weeks

  6. The Mean Value in Treatment Satisfaction (Patient's Global Impression of Change )

    The PGIC has a minimum possible score of 1 (very much improved) and a maximum possible score of 7 (very much worse). Subjects was asked to use a categorical scale with 7 categories to describe their global impression of change (PGIC) with study drug treatment. Subjects recorded their impression of change on paper at Weeks 2, 4, and 8 (EOT). Although the change from baseline (run-in phase \[Days -7 to -1\]) was specified as an outcome in this study, it was not calculated because the target enrollment was not met and no meaningful statistical analysis could be expected. Therefore, the mean value of patients at each point is shown instead.

    Time frame: 2 weeks, 4 weeks and 8 weeks

  7. Change From Baseline in QoL Assessment (5-D-Itch Scale)

    The 5-D-Itch scale has a minimum possible score of 5 (better) and a maximum possible score of 25 (worse). Subjects was asked to assess QoL by means of the 5D-Itch-Scale at Baseline, Weeks 2, 4, and 8 (EOT). The 5D-Itch Scale is a 5-item (duration, degree, direction, disability, and distribution) multidimensional measure of pruritus itch. Change from Baseline (the Run-in Phase \[Days -7 to -1\]) were assessed. Amount of change score of plus indicates worsening, and minus indicates improvement.

    Time frame: 2 weeks, 4 weeks and 8 weeks

  8. The Number of Patients in Excoriation

    Investigator and/or the designated medically qualified staff assessed the subject's excoriation at Baseline, and weekly thereafter, by completing the subject's answers to the following questions: Excoriation present? Yes/No If yes, please rate the severity: Mild/Moderate/Severe Although the change from baseline (run-in phase \[Days -7 to -1\]) was specified as an outcome in this study, it was not calculated because the target enrollment was not met and no meaningful statistical analysis could be expected. Therefore, the number of patients at each point is shown instead.

    Time frame: 2 weeks, 4 weeks and 8 weeks

Secondary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    The number of subjects with at least 1 treatment-emergent adverse event (TEAE). Please see the adverse event table for specific.

    Time frame: 8 weeks

07

Results

Posted Feb 9, 2022

Participant flow

Participant flow — Overall Study
MilestoneMT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlacebo
Started10131111
Completed813910
Not completed2021
Withdrew: Adverse event1010
Withdrew: Unable to visit clinic to obtain study drug due to hospitalization1000
Withdrew: Subject was noncompliant with study drug after experiencing aes; was not discontinued due to the aes0010
Withdrew: Randomization error0001

Outcome measures

PrimaryChange From Baseline in Worst-itching 11-point Numerical Rating Scale (NRS)

The subject indicated the number on the line from left (0:no itching) to right (10:worst itch I have ever experienced). Assessments was made twice daily using an electronic Patient Reported Outcomes (ePRO) device from the Screening Visit to the Follow-up Visit (Week 9). The 2 daily assessments was separated by 12 h, at approximately 8 am and at approximately 8 pm. Subjects selected the number that best described the worst itch during the day (assessed at approximately 8 pm) or during the night (assessed at approximately 8 am). The day or night score, whichever was greater, was used to calculate the weekly average score and changes from baseline (average over the Run-in Phase \[Days -7 to -1\]) score in weekly average at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.

Time frame:
2 weeks, 4 weeks and 8 week
Reported as:
Mean · score on a scale
Change From Baseline in Worst-itching 11-point Numerical Rating Scale (NRS)
score on a scaleMT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlacebo
At 2 weeks-1.11 ± 1.224-1.19 ± 1.177-1.12 ± 0.828-2.27 ± 2.774
At 4 weeks-1.41 ± 2.032-2.12 ± 2.527-1.85 ± 1.392-2.25 ± 3.114
At 8 weeks (EOT)-2.33 ± 2.269-3.13 ± 2.833-3.42 ± 2.262-3.39 ± 3.614
PrimaryChange From Baseline in Worst-itching Visual Analog Scale (VAS)

The subject placed a single vertical mark on the line of a VAS corresponding to degree of itching intensity from left (no itching) to right (worst itch I have ever experienced). The VAS represents a 100 mm line. It consists of 101 selectable regions and the subject's score on the VAS will correspond to the region (0 to 100) selected on the line. Assessments was made twice daily using an ePRO device from the Screening Visit to the Follow-up Visit (Week 9). The 2 daily assessments was separated by 12 h, in the morning at approximately 8 am and in the night at approximately 8 pm. Subjects put a single vertical mark on the line to show the intensity of your worst itching during the day or during the night. The day or night score, whichever was greater, was used to calculate the weekly average score and changes from baseline in weekly average at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.

Time frame:
2 weeks, 4 weeks and 8 weeks
Reported as:
Mean · mm
Change From Baseline in Worst-itching Visual Analog Scale (VAS)
mmMT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlacebo
At 2 weeks-8.77 ± 15.158-12.27 ± 12.154-6.56 ± 18.778-21.09 ± 26.719
At 4 weeks-14.17 ± 22.631-19.46 ± 25.097-21.24 ± 20.300-23.63 ± 31.239
At 8 weeks (EOT)-23.06 ± 23.686-29.16 ± 27.628-24.49 ± 42.732-30.09 ± 31.582
PrimaryChange From Baseline in Itch Severity Score

The subject performed an assessment on day and nighttime symptoms of itch and effect of itch on sleep using a 5-point ordinal scale of itchiness (0 = none, 1 = mild, 2 = Moderate, 3=Severe, 4 = very severe). Assessments was made during each dialysis treatment (3x/week) and recorded on paper from the Screening Visit to the Follow-up Visit (Week 9). Change from Baseline (average over the Run-in Phase \[Days -7 to -1\]) in Weekly Averages of Itch Severity Score were assessed and score at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.

Time frame:
2 weeks, 4 weeks and 8 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Itch Severity Score
score on a scaleMT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlacebo
At 2 weeks-0.77 ± 0.721-0.77 ± 0.542-0.43 ± 0.872-0.92 ± 1.106
At 4 weeks-0.81 ± 0.835-1.08 ± 0.741-1.30 ± 0.885-0.90 ± 1.275
At 8 weeks (EOT)-1.13 ± 1.003-1.49 ± 0.919-1.28 ± 1.094-1.28 ± 1.197
PrimaryChange From Baseline in Sleep Quality Assessment

The PSQI has a minimum possible score of 0 (better sleep quality) and a maximum possible score of 10 (worse sleep quality). Subjects was asked to rate their sleep experience during the previous week. Pittsburgh Sleep Quality Index (PSQI) modified assessment was made during the dialysis treatment 1x/week every week and recorded on paper from the Screening Visit to the Follow-up Visit (Week 9).Change from Baseline (the Run-in Phase \[Days -7 to -1\]) were assessed and score at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.

Time frame:
2 weeks, 4 weeks and 8 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Sleep Quality Assessment
score on a scaleMT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlacebo
At 2 weeks-0.4 ± 1.06-0.2 ± 2.17-0.2 ± 1.64-1.0 ± 1.15
At 4 weeks-0.4 ± 1.92-0.3 ± 1.65-1.1 ± 1.36-0.1 ± 1.36
At 8 weeks (EOT)-1.1 ± 1.35-0.6 ± 1.62-1.2 ± 1.55-0.4 ± 1.59
PrimaryChange From Baseline in QoL Assessment (Skindex-10)

The Skindex-10 has a minimum possible score of 0 (itching not bothersome) and a maximum possible score of 60 (itching very bothersome). The Skindex-10 is a self-administered questionnaire used to evaluate the health-related QoL in UP. It is comprised of 10 questions, adopted for pruritus from the Skindex-16, a widely used instrument for a variety of skin disease. Subjects was asked to identify on paper at Baseline and Weeks 2, 4, and 8 (EOT) what has bothered them most during the past week by marking along a scale 0 to 6 boxes from "never bothered" to "always bothered. Change from Baseline (the Run-in Phase \[Days -7 to -1\]) were assessed. Amount of change score of plus indicates worsening, and minus indicates improvement.

Time frame:
2 weeks, 4 weeks and 8 weeks
Reported as:
Mean · score on a scale
Change From Baseline in QoL Assessment (Skindex-10)
score on a scaleMT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlacebo
At 2 weeks-5.5 ± 8.55-11.6 ± 11.16-5.4 ± 9.27-13.6 ± 15.21
At 4 weeks-0.5 ± 14.99-16.5 ± 15.00-16.4 ± 14.55-13.7 ± 17.68
At 8 weeks (EOT)-11.9 ± 5.61-23.5 ± 15.52-19.2 ± 14.59-16.3 ± 14.63
PrimaryThe Mean Value in Treatment Satisfaction (Patient's Global Impression of Change )

The PGIC has a minimum possible score of 1 (very much improved) and a maximum possible score of 7 (very much worse). Subjects was asked to use a categorical scale with 7 categories to describe their global impression of change (PGIC) with study drug treatment. Subjects recorded their impression of change on paper at Weeks 2, 4, and 8 (EOT). Although the change from baseline (run-in phase \[Days -7 to -1\]) was specified as an outcome in this study, it was not calculated because the target enrollment was not met and no meaningful statistical analysis could be expected. Therefore, the mean value of patients at each point is shown instead.

Time frame:
2 weeks, 4 weeks and 8 weeks
Reported as:
Mean · units on a scale
The Mean Value in Treatment Satisfaction (Patient's Global Impression of Change )
units on a scaleMT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlacebo
2 weeks3.1 ± 0.643.1 ± 1.513.0 ± 0.872.6 ± 1.07
4 weeks3.3 ± 0.712.8 ± 1.362.5 ± 0.932.8 ± 1.09
8 weeks2.6 ± 0.981.9 ± 0.902.1 ± 1.172.2 ± 1.30
PrimaryChange From Baseline in QoL Assessment (5-D-Itch Scale)

The 5-D-Itch scale has a minimum possible score of 5 (better) and a maximum possible score of 25 (worse). Subjects was asked to assess QoL by means of the 5D-Itch-Scale at Baseline, Weeks 2, 4, and 8 (EOT). The 5D-Itch Scale is a 5-item (duration, degree, direction, disability, and distribution) multidimensional measure of pruritus itch. Change from Baseline (the Run-in Phase \[Days -7 to -1\]) were assessed. Amount of change score of plus indicates worsening, and minus indicates improvement.

Time frame:
2 weeks, 4 weeks and 8 weeks
Reported as:
Mean · score on a scale
Change From Baseline in QoL Assessment (5-D-Itch Scale)
score on a scaleMT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlacebo
At 2 weeks-2.8 ± 2.12-3.3 ± 2.46-3.0 ± 2.62-6.1 ± 5.84
At 4 weeks-1.6 ± 4.17-5.1 ± 3.80-5.6 ± 3.16-5.7 ± 5.02
At 8 weeks-3.7 ± 3.90-8.6 ± 4.25-6.2 ± 5.01-7.6 ± 4.53
PrimaryThe Number of Patients in Excoriation

Investigator and/or the designated medically qualified staff assessed the subject's excoriation at Baseline, and weekly thereafter, by completing the subject's answers to the following questions: Excoriation present? Yes/No If yes, please rate the severity: Mild/Moderate/Severe Although the change from baseline (run-in phase \[Days -7 to -1\]) was specified as an outcome in this study, it was not calculated because the target enrollment was not met and no meaningful statistical analysis could be expected. Therefore, the number of patients at each point is shown instead.

Time frame:
2 weeks, 4 weeks and 8 weeks
Reported as:
Count of participants · Participants
The Number of Patients in Excoriation
ParticipantsMT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlacebo
Baseline — Excoriation not present7677
Baseline — Mild2432
Baseline — Moderate1212
Baseline — Severe0000
Baseline — Missing0000
2 weeks — Excoriation not present6777
2 weeks — Mild2523
2 weeks — Moderate0000
2 weeks — Severe0000
2 weeks — Missing0000
4 weeks — Excoriation not present61177
4 weeks — Mild2212
4 weeks — Moderate0001
4 weeks — Severe0000
4 weeks — Missing0000
8 weeks — Excoriation not present6997
8 weeks — Mild1201
8 weeks — Moderate0100
8 weeks — Severe0001
8 weeks — Missing0000
SecondaryNumber of Participants With Adverse Events as a Measure of Safety and Tolerability

The number of subjects with at least 1 treatment-emergent adverse event (TEAE). Please see the adverse event table for specific.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
ParticipantsMT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlacebo
Number of Participants With Adverse Events as a Measure of Safety and Tolerability6596

Adverse events

Collected over 8 weeks for treatment phase + 1 week follow-up visit after last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MT-9938 2.5μg0/10 (0%)4/10 (40%)2/10 (20%)
MT-9938 5μg0/13 (0%)0/13 (0%)2/13 (15.4%)
MT-9938 10μg0/11 (0%)3/11 (27.3%)5/11 (45.5%)
Placebo0/11 (0%)2/11 (18.2%)3/11 (27.3%)
Most frequent serious events
Most frequent serious events
EventMT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlacebo
Cardiac Failure CongestiveCardiac disorders0/100/132/110/11
DiverticulitisInfections and infestations1/100/130/110/11
Fluid OverloadMetabolism and nutrition disorders1/100/130/110/11
HypercalcaemiaMetabolism and nutrition disorders1/100/130/110/11
Pancreatitis RelapsingGastrointestinal disorders1/100/130/110/11
CellulitisInfections and infestations0/100/131/110/11
PneumoniaInfections and infestations0/100/130/111/11
DyspnoeaRespiratory, thoracic and mediastinal disorders0/100/131/110/11
Pleural EffusionRespiratory, thoracic and mediastinal disorders0/100/131/110/11
AstheniaGeneral disorders0/100/130/111/11
Most frequent other events
Most frequent other events
EventMT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlacebo
InsomniaPsychiatric disorders1/101/135/111/11
NauseaGastrointestinal disorders1/100/133/111/11
HyperprolactinaemiaEndocrine disorders1/101/130/111/11

Baseline characteristics

ITT

Age, Continuous
Age, Continuous(years)MT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlaceboTotal
Mean58.5 ± 10.6254.6 ± 12.7855.3 ± 13.6455.2 ± 12.9455.8 ± 12.25
Sex: Female, Male
Sex: Female, Male(Participants)MT-9938 2.5μgMT-9938 5μgMT-9938 10μgPlaceboTotal
Female522413
Male5119732
08

Study locations

4 sites
  • Los Angeles, California, United States
  • New York, New York, United States
  • Rosedale, New York, United States
  • San Antonio, Texas, United States
09

References and documents

Publications

  • Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev. 2020 Dec 7;12(12):CD011393. doi: 10.1002/14651858.CD011393.pub2. PubMed 33283264 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2022, 7 years 11 months after primary completion. A results delay was requested in Oct 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2012
First posted
Aug 8, 2012
Start
Sep 2012
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results delay requested
Oct 20, 2015
Results first posted
Feb 9, 2022
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01660243
Lead sponsor
Toray Industries, Inc
Responsible party
Sponsor
First posted
Aug 8, 2012
Start date
Sep 2012
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Feb 9, 2022
Last update
Feb 9, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRK 820

Start the discussion